Melanoma Adjuvant Therapy

Hematology/Oncology Clinics of North America

Volumn 28, Issue 3, 2014, Pages 471-489

  Tarhini, Ahmad A ^a   Thalanayar, Prashanth M ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Adjuvant; Interferon; Ipilimumab; Melanoma

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; BCG VACCINE; BIOLOGICAL MARKER; CIMETIDINE; CISPLATIN; DABRAFENIB; DACARBAZINE; GSK 2132231A; INTERLEUKIN 2; IPILIMUMAB; LEVAMISOLE; MELANOMA VACCINE; ONAMELATUCEL L; PEGINTERFERON ALPHA2B; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB; VINBLASTINE; CANCER VACCINE;

CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; DRUG DOSE COMPARISON; DRUG MEGADOSE; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; LIVER TOXICITY; LOW DRUG DOSE; MELANOMA; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT INDICATION; ADJUVANT CHEMOTHERAPY; DOSE RESPONSE; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; SKIN NEOPLASMS; TREATMENT OUTCOME;

CANCER VACCINES; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; MELANOMA; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84901421946     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2014.02.004     Document Type: Review

References (55)

1. Siegel R., Ma J., Zou Z., et al. Cancer statistics, 2014. CA Cancer J Clin 2014, 64(1):9-29.
2. Balch C.M., Gershenwald J.E., Soong S.J., et al. Final version of 2009 AJCC melanoma staging and classification. JClin Oncol 2009, 27:6199-6206.
3. Sosman J.A., Moon J., Tuthill R.J., et al. Aphase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer 2011, 117:4740-06.
4. Tarhini A.A., Gogas H., Kirkwood J.M. IFN-alpha in the treatment of melanoma. JImmunol 2012, 189:3789-3793.
5. Moschos S.J., Edington H.D., Land S.R., et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. JClin Oncol 2006, 24:3164-3171.
6. Creagan E.T., Dalton R.J., Ahmann D.L., et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. JClin Oncol 1995, 13:2776-2783.
7. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. JClin Oncol 1996, 14:7-17.
8. Kirkwood J.M., Ibrahim J.G., Sondak V.K., et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. JClin Oncol 2000, 18:2444-2458.
9. Kirkwood J.M., Ibrahim J.G., Sosman J.A., et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. JClin Oncol 2001, 19:2370-2380.
10. Kirkwood J.M., Ibrahim J., Lawson D.H., et al. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. JClin Oncol 2001, 19:1430-1436.
11. Chao C., Wong S.L., Ross M.I., et al. Patterns of early recurrence after sentinel lymph node biopsy for melanoma. Am J Surg 2002, 184:520-524. [discussion: 5].
12. Chiarion-Sileni V., Guida M., Romanini A., et al. Intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III melanoma: arandomized phase III Italian Melanoma Intergroup (IMI) trial [ISRCTN75125874]. JClin Oncol (ASCO Annual Meeting Abstracts) 2011, 29(Suppl 15):8506.
13. Gogas H., Bafaloukos D., Ioannovich J., et al. Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year-a Hellenic Cooperative Oncology Group study. Anticancer Res 2004, 24:1947-1952.
14. Agarwala S.S., Lee S.J., Flaherty L.E., et al. Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (intergroup trial E 1697), 2011 ASCO Annual Meeting Abstracts. JClin Oncol 2011, 29:8505.
15. Kleeberg U.R., Suciu S., Brocker E.B., et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness≥3 mm) or regional lymph node metastasis. Eur J Cancer 2004, 40:390-402.
16. Cascinelli N., Bufalino R., Morabito A., et al. Results of adjuvant interferon study in WHO melanoma programme. Lancet 1994, 343:913-914.
17. Hancock B.W., Wheatley K., Harris S., et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study-United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. JClin Oncol 2004, 22:53-61.
18. Cameron D.A., Cornbleet M.C., Mackie R.M., et al. Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study. Br J Cancer 2001, 84:1146-1149.
19. Hauschild A., Weichenthal M., Rass K., et al. Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of≥= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. JClin Oncol 2010, 28:841-846.
20. Eggermont A.M., Suciu S., MacKie R., et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005, 366:1189-1196.
21. Eggermont A.M., Suciu S., Santinami M., et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008, 372:117-126.
22. Grob J.J., Dreno B., de la Salmoniere P., et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998, 351:1905-1910.
23. Garbe C., Radny P., Linse R., et al. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol 2008, 19:1195-1201.
24. Pehamberger H., Soyer H.P., Steiner A., et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. JClin Oncol 1998, 16:1425-1429.
25. Mocellin S., Pasquali S., Rossi C.R., et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. JNatl Cancer Inst 2010, 102:493-501.
26. Eggermont A.M., Spatz A., Lazar V., et al. Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity?. Curr Opin Oncol 2012, 24:137-140.
27. Gogas H., Ioannovich J., Dafni U., et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. NEngl J Med 2006, 354:709-718.
28. Tarhini A.A., Stuckert J., Lee S., et al. Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. JClin Oncol 2009, 27:38-44.
29. Meyer S., Wild P.J., Vogt T., et al. Methylthioadenosine phosphorylase represents a predictive marker for response to adjuvant interferon therapy in patients with malignant melanoma. Exp Dermatol 2010, 19:e251-e257.
30. Ballo M.T., Ang K.K. Radiation therapy for malignant melanoma. Surg Clin North Am 2003, 83:323-342.
31. Ballo M.T., Bonnen M.D., Garden A.S., et al. Adjuvant irradiation for cervical lymph node metastases from melanoma. Cancer 2003, 97:1789-1796.
32. Agrawal S., Kane J.M., Guadagnolo B.A., et al. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer 2009, 115:5836-5844.
33. Strojan P., Jancar B., Cemazar M., et al. Melanoma metastases to the neck nodes: role of adjuvant irradiation. Int J Radiat Oncol Biol Phys 2010, 77:1039-1045.
34. Burmeister B.H., Henderson M.A., Ainslie J., et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol 2012, 13:589-597.
35. Creagan E.T., Cupps R.E., Ivins J.C., et al. Adjuvant radiation therapy for regional nodal metastases from malignant melanoma: a randomized, prospective study. Cancer 1978, 42:2206-2210.
36. Burmeister B.H., Smithers B.M., Poulsen M., et al. Radiation therapy for nodal disease in malignant melanoma. World J Surg 1995, 19:369-371.
37. Corry J., Smith J.G., Bishop M., et al. Nodal radiation therapy for metastatic melanoma. Int J Radiat Oncol Biol Phys 1999, 44:1065-1069.
38. Stevens G., Thompson J.F., Firth I., et al. Locally advanced melanoma: results of postoperative hypofractionated radiation therapy. Cancer 2000, 88:88-94.
39. Ballo M.T., Ross M.I., Cormier J.N., et al. Combined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys 2006, 64:106-113.
40. Burmeister B.H., Mark Smithers B., Burmeister E., et al. Aprospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma-Trans Tasman Radiation Oncology Group (TROG) Study 96.06. Radiother Oncol 2006, 81:136-142.
41. Veronesi U., Adamus J., Aubert C., et al. Arandomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. NEngl J Med 1982, 307:913-916.
42. Lejeune F., Macher E., Kleeberg U., et al. An assessment of DTIC versus levamisole and placebo in the treatment of high risk stage I patients after removal of a primary melanoma of the skin, a phase III adjuvant study. EORTC protocol 18761. Eur J Cancer Clin Oncol 1988, 24:881-890.
43. Fisher R.I., Terry W.D., Hodes R.J., et al. Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial. Surg Clin North Am 1981, 61:1267-1277.
44. Koops H.S., Vaglini M., Suciu S., et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. JClin Oncol 1998, 16:2906-2912.
45. Flaherty LE, Moon J, Atkins MB, etal. Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): an intergroup study of CALGB, COG, ECOG, and SWOG. J Clin Oncol (ASCO Annual Meeting) 2012;30(Suppl 15):8504.
46. Kruit W., Suciu S., Dreno B., et al. Active immunization toward the MAGE-A3 antigen in patients with metastatic melanoma: four-year follow-up results from a randomized phase II study (EORTC16032-18031). 2011 ASCO Annual Meeting Abstracts. JClin Oncol 2011, 29(Suppl 15):8535.
47. Hersey P., Coates A.S., McCarthy W.H., et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. JClin Oncol 2002, 20:4181-4190.
48. Morton D., Mozzillo N., Thompson J.F., et al. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. 2007 ASCO Annual Meeting Proceedings. JClin Oncol 2007, 25(18S):8508.
49. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. NEngl J Med 2010, 363:711-723.
50. Wolchok J.D., Thomas L., Bondarenko I.N., et al. Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma. ASCO Annual Meeting Proceedings. JClin Oncol 2011, 29(Suppl). [abstract: LBA5].
51. Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. NEngl J Med 2011, 364:2507-2516.
52. Atkins M.B., Hsu J., Lee S., et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. JClin Oncol 2008, 26:5748-5754.
53. Keilholz U., Punt C.J., Gore M., et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. JClin Oncol 2005, 23:6747-6755.
54. Tarhini A.A., Pahuja S., Kirkwood J.M. Neoadjuvant therapy for high-risk bulky regional melanoma. JSurg Oncol 2011, 104:386-390.
55. Tarhini A.A., Edington H., Butterfield L.H. Neoadjuvant ipilimumab in locally/regionally advanced melanoma: clinical outcome and biomarker analysis. JClin Oncol 2012, 30(Suppl 30). [abstract: 8533].